GLPwatch
Papers (9189)
Page 61 of 154, ranked by citation count.
- Liraglutide for the treatment of type 2 diabetes.
- Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
- Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.
- Adult Murine Pancreatic Progenitors Require Epidermal Growth Factor and Nicotinamide for Self-Renewal and Differentiation in a Serum- and Conditioned Medium-Free Culture.
- Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) Study.
- The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1<sup>G93A</sup> and TDP-43<sup>Q331K</sup> transgenic mouse models of ALS.
- Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.
- Extrinsic factors promoting in vitro differentiation of insulin-secreting cells from human adipose tissue-derived mesenchymal stem cells.
- Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
- Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.
- Exendin-4 pretreated adipose derived stem cells are resistant to oxidative stress and improve cardiac performance via enhanced adhesion in the infarcted heart.
- Insufficient sleep predicts poor weight loss maintenance after 1 year.
- A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
- Reduction in TNF alpha and oxidative stress by liraglutide: Impact on ketamine-induced cognitive dysfunction and hyperlocomotion in rats.
- Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease.
- Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.
- Indirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in mice.
- Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
- The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice.
- Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
- Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.
- GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy.
- Enhanced protection against renal ischemia-reperfusion injury with combined melatonin and exendin-4 in a rodent model.
- GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers.
- Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride.
- Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
- Gut hormones and appetite regulation.
- Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
- Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
- Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male Snord116 deletion mouse model for Prader-Willi syndrome.
- Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model.
- Successful Pregnancy after Improving Insulin Resistance with the Glucagon-Like Peptide-1 Analogue in a Woman with Polycystic Ovary Syndrome: A Case Report and Review of the Literature.
- Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.
- Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study.
- High dosage of Exendin-4 increased early insulin secretion in differentiated beta cells from mouse embryonic stem cells.
- Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
- Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
- A case report: Liraglutide as a novel treatment option in late dumping syndrome.
- Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.
- Perspectives in weight control in diabetes - Survodutide.
- Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA<sub>1c</sub> levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
- Origin and convergent evolution of exendin genes.
- Targeted ion parking for the quantitation of biotherapeutic proteins: concepts and preliminary data.
- Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.
- Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.
- Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
- Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro.
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
- Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.
- Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.
- DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
- An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
- The effect of obesity pharmacotherapy on body composition, including muscle mass.
- Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.
- Exendin-4 protects HUVECs from t-BHP-induced apoptosis via PI3K/Akt-Bcl-2-caspase-3 signaling.
- The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.
- Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.